{"filings":[{"id":501239,"accession_number":"0001829126-26-005421","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-05-18T21:00:15+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NeOnc reports Q1 net loss $8.8M; NEO212 Phase 1 complete, NEO100 interim data Aug 2026","event_type":"earnings","confidence":"high","bullets":["Net loss $8.8M ($0.38/diluted) vs $32.3M ($1.78) in Q1 2025; G&A down to $489K, R&D up to $1.29M.","Cash $138,601 at Mar 31; $10M PIPE from Cinctive Capital and $10M undrawn credit line fund ops into Sep 2026.","NEO212 Phase 1 complete, RP2D set at 610 mg; FDA End-of-Phase 1 meeting planned for potential registrational Phase 2.","NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected August 2026.","Appointed David Choi as CAO; CEO Amir Heshmatpour purchased >$500k of NTHI shares in open market."],"consensus_eps_estimate":-0.2244,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97043,"accession_number":"0001829126-26-003882","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"NeOnc Technologies raises $2M in stock and warrant offering for NEO216 preclinical trials","event_type":"other_material","confidence":"high","bullets":["Initial closing of 277,777 shares and warrants at $7.20/share for ~$2M from one institutional investor.","Total offering up to 406,694 shares and warrants at $7.20 per share; warrants exercisable at $9.00.","Net proceeds to fund NEO216 preclinical trials.","Fourth securities purchase agreement; offering terminates April 30, 2026.","Shares and warrants issued in unregistered transaction under Section 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97042,"accession_number":"0001829126-26-003566","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc CEO buys ~$300k NTHI stock; FY2025 net loss $62M, mostly non-cash; clinical catalysts ahead","event_type":"other_material","confidence":"high","bullets":["CEO Amir Heshmatpour purchased ~$300k of NTHI common stock in the past week, signaling confidence.","FY2025 net loss ~$62M; ~$45.2M was non-cash stock comp ($35.6M) and one-time listing fees ($9.6M); normalized cash op ex ~$10.1M.","NEO100 Phase 2a interim data readout expected ~August 2026 (within ~4 months).","NEO212 Type B End-of-Phase FDA meeting within ~4 weeks to align on potential registrational Phase 2 study.","Q1 2026 private placement raised ~$13M gross; proceeds used to repay convertible debt and obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97041,"accession_number":"0001829126-26-003401","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"NeOnc Technologies enters ATM equity distribution agreement for up to $75M common stock","event_type":"other_material","confidence":"high","bullets":["Agreement with BTIG, LLC and A.G.P./Alliance Global Partners for at-the-market offering up to $75M of common stock.","Placement agents receive 3.0% commission on shares sold; sales may occur on Nasdaq or other trading markets.","Offering under Form S-3 (File No. 333-294845) declared effective April 9, 2026; prospectus supplement filed April 10, 2026.","Company may suspend or terminate offering with two days' notice; agents may terminate with one day's notice.","Shares sold at market prices; no obligation to sell any shares; proceeds for general corporate purposes (implied)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97040,"accession_number":"0001829126-26-003165","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NeOnc Q4 net loss $62.1M ($3.20/sh); NEO212 Phase 1 complete, NEO100 Phase 2a enrolled","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $62.1M ($3.20 diluted EPS) vs $11.9M ($0.69) in Q4 2024; G&A surged to $4.8M from $1.7M.","NEO212 Phase 1 complete; RP2D set at 610 mg; company plans Type B End-of-Phase 1 FDA meeting for potential registrational study.","NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected ~August 2026.","PIPE financing anchored by $10M commitment from Cinctive Capital Management.","Leadership additions: Amir Heshmatpour named CEO, David Choi appointed CAO; two neuro-oncologists joined SAB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111497,"accession_number":"0001829126-26-002610","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"NeOnc Technologies raises $1M in third private placement; sells 138,889 shares at $7.20 with warrants","event_type":"other_material","confidence":"high","bullets":["Entered third securities purchase agreement on March 20, 2026: up to 545,583 shares at $7.20, with five-year warrants at $9.00.","Initial closing of 138,889 shares and warrants to one investor for $1,000,000.","Proceeds intended for working capital purposes.","Offering terminates on April 30, 2026.","Company to file resale registration statement for shares and warrant shares within 10 days of filing 2025 Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111496,"accession_number":"0001829126-26-002331","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"NeOnc Technologies appoints David Choi as Chief Accounting Officer","event_type":"leadership","confidence":"high","bullets":["David Choi appointed CAO effective March 12, 2026; base salary $162,500/year.","Grant of 170,000 restricted shares under 2023 equity plan; 53,333 vested immediately.","58,333 shares vest at one-year anniversary; 58,334 shares are performance-based.","Choi is a CPA with prior roles at Blythe Global Advisors, Grant Thornton, and EY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111495,"accession_number":"0001829126-26-002020","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc reports Phase 1 dose-escalation results for NEO212; RP2D set at 610 mg","event_type":"other_material","confidence":"high","bullets":["MTD reached at 810 mg (Cohort 5) with second DLT; dose escalation halted.","Recommended Phase 2 Dose (RP2D) set at 610 mg; Phase 2a metastasis start at 400 mg.","Early efficacy signals: partial response in recurrent GBM (~60% tumor reduction after 21 cycles) and stable disease in brain metastasis.","No clinically meaningful myelosuppression; 39x lower AIC vs TMZ indicating lower toxicity.","Type B FDA meeting to be requested for accelerated approval pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111494,"accession_number":"0001829126-26-001927","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NeOnc pays $737,921 to settle Fox Infused IP dispute","event_type":"litigation","confidence":"high","bullets":["Paid $737,920.77 on Feb 27, 2026, including $137,920.77 in interest, settling arbitration.","Original settlement terms required $600k payment within 5 business days of IPO or March 31, 2024.","Fox Infused had sued NeOnc in 2023 over terminated IP license and supply agreement.","Arbitration case (AAA Case No. 01-23-0002-5020) is now closed and dispute resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111493,"accession_number":"0001829126-26-001885","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"NeOnc Technologies enters securities purchase agreement for up to 746,973 shares, initial closing raises $1.45M","event_type":"other_material","confidence":"high","bullets":["New Securities Purchase Agreement for up to 746,973 shares at $7.20/share plus 5-yr warrants at $9.00/share.","Initial closing on Feb 25, 2026: 201,390 shares and warrants sold to four investors for $1,450,004.","Net proceeds to be used for working capital; offering terminated Feb 28, 2026.","Combined with prior January closings, total offering up to 2,222,222 shares; earlier tranches raised ~$10.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111492,"accession_number":"0001829126-26-001755","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc to present Phase 1 dose-escalation data from NEO212 trial on March 4 call","event_type":"other_material","confidence":"high","bullets":["Investor conference call scheduled for March 4, 2026 at 9:00 a.m. ET to present initial Phase 1 dose-escalation results from NEO212-01 trial.","Phase 1 portion evaluated oral NEO212 in CNS malignancies; data includes safety, toxicity, PK, and regulatory next steps.","Featured participants: Dr. Henry Friedman (Duke), Dr. Alexandra Miller (NYU Langone), plus NTHI management.","NEO212 is a proprietary bioconjugated temozolomide platform with FDA Fast-Track and IND status for CNS cancers.","No specific data disclosed in this release; full presentation will occur on the call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111491,"accession_number":"0001829126-26-000757","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"NeOnc Technologies raises $10M via private placement of 1.39M shares and warrants","event_type":"other_material","confidence":"high","bullets":["Sold 1,388,888 shares at $7.20 and 1,388,888 warrants at $9.00 exercise to a single institutional investor for $10M.","Five-year warrants allow purchase of additional shares; total potential issuance up to 2,222,222 shares and warrants.","Proceeds to be used for debt repayment and working capital.","Company to file resale registration statement within 10 days.","Securities issued under Section 4(a)(2) exemption; not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128121,"accession_number":"0001829126-25-010101","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc reports updated NEO100 data: 24% radiographic remission, 44% PFS-6 in recurrent IDH1-mutant astrocytoma","event_type":"other_material","confidence":"high","bullets":["6 of 25 patients (24%) achieved radiographic remission vs <8% historical salvage therapies.","44% achieved 6-month progression-free survival (PFS-6), exceeding historical 21-31% benchmarks.","9 of 25 patients (36%) remain alive ≥18 months post NEO100 initiation; no significant toxicity seen.","All patients had recurrent WHO Grade III/IV IDH1-mutant astrocytoma; data from Phase 1/2a and compassionate use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128120,"accession_number":"0001829126-25-009754","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"NeOnc raises $1M from Saad Naja; AI study shows ultrasound boosts NEO100 against brain tumors","event_type":"other_material","confidence":"high","bullets":["Issued 111,732 shares at $8.95 to Saad Naja, raising gross proceeds of ~$1M for working capital.","Preclinical collaboration with USC (bioRxiv) shows NEO100 combined with focused ultrasound enhances tumor killing in glioblastoma, medulloblastoma, meningioma, and metastases.","AI-trained platform using 200+ molecular descriptors identified NEO100 as a leading sonosensitizer; 3D-bioprinted organoids validated results in days vs. weeks.","Results support moving NEO100-plus-ultrasound into future clinical trials for multiple primary and metastatic brain tumors.","CEO Heshmatpour says findings expand NEO100's commercial and clinical opportunity beyond current indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128119,"accession_number":"0001829126-25-009221","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"NeOnc Q3 net loss $8.6M ($0.45/diluted); NEO100 Phase 2a shows 21% response rate; board changes","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.6M ($0.45 diluted EPS) vs $2.2M ($0.12) in Q3 2024; G&A up $903k vs $244k YoY.","NEO100 Phase 2a in recurrent brain cancer: 21% response rate vs <8% historical; 44% six-month PFS; 33% alive >=18 months.","NEO212 received FDA authorization to proceed to Phase II; Phase I final cohort dosing on track for Q4 2025.","NuroMENA subsidiary signed $50M strategic partnership with Quazar Investment, appointed H.H. Sheikh Nahyan as Exec Chairman.","Dr. Ming-Fu Chiang re-elected to Board after Ishwar K. Puri resigned due to USC objection."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":39990.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128118,"accession_number":"0001829126-25-009076","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NEO100 yields 21% radiographic response & 44% 6mo PFS in recurrent IDH1-mutant gliomas","event_type":"other_material","confidence":"high","bullets":["Radiographic response rate of 21% (5/24) in recurrent Grade III/IV IDH1-mutant astrocytoma, exceeding <8% benchmark for salvage therapies.","Six-month progression-free survival (PFS-6) of 44% (8/18 evaluable) vs historical 21-31%.","33% of patients (8/24) alive ≥18 months post-NEO100 initiation; median overall survival 88 months.","No significant toxicity with chronic intranasal dosing; enrollment completed at 25 patients.","CEO calls data a potential paradigm shift; company advancing to Phase 2b/3 and global trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128117,"accession_number":"0001829126-25-008959","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc to host Nov 12 call to update on NEO100-1 trial and compassionate use data","event_type":"other","confidence":"high","bullets":["Investor call on Nov 12, 2025 at 9:00 a.m. ET to present data updates from Phase 1/2a NEO100-1 trial.","Discussion to include MRI radiographic response, progression-free survival (PFS), and overall survival (OS) trends.","Participants include Duke and NYU Langone neuro-oncologists; management team present.","No specific clinical results disclosed in the press release; call may provide new data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128116,"accession_number":"0001829126-25-008902","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NeOnc Technologies appoints Amir Heshmatpour as CEO; founder Dr. Thomas Chen transitions to CMO/CSO","event_type":"leadership","confidence":"high","bullets":["Dr. Thomas Chen resigns as CEO, becomes Chief Medical Officer and Chief Scientific Officer, retains Vice Chairman role.","Amir Heshmatpour appointed CEO effective Oct 31, 2025, in addition to President and Executive Chairman roles.","Heshmatpour to receive $1/year salary and 1.2M restricted stock shares with vesting schedule.","Press release highlights $50M strategic partnership with Quazar Investment and expansion of Scientific Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128115,"accession_number":"0001829126-25-008611","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sheikh Nahyan bin Zayed Al Nahyan becomes Executive Chairman of NeOnc's Middle East subsidiary","event_type":"leadership","confidence":"high","bullets":["Sheikh Nahyan bin Zayed Al Nahyan assumes Executive Chairman of NuroMENA Holdings Ltd., NeOnc's Middle East subsidiary.","Amir Heshmatpour, current Executive Chairman of NeOnc, transitions to Vice Chairman of NuroMENA.","Press release references support from a sovereign wealth fund, but no specific fund or amount disclosed.","Event announced via press release dated October 28, 2025; no financial impact quantified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128114,"accession_number":"0001829126-25-008052","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc sets Oct 23 closing for $50M partnership with Quazar Investment after UAE approvals","event_type":"other_material","confidence":"high","bullets":["Closing of $50M strategic partnership with Quazar Investment by Oct 23 after UAE tax/regulatory approvals.","$15M of funds allocated for Phase 2B clinical trials and infrastructure in UAE and MENA region.","Four upcoming clinical trials: NEO100-01, NEO100-02, NEO212 (Phase 2a/2b), and NEO100-03 (Phase 1 pediatric).","NuroMENA Holdings, the Abu Dhabi-based operating subsidiary, incorporated on August 6, 2025.","Quazar Investment has over $3.3B in AUM; partnership involves significant equity investment in NeOnc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128113,"accession_number":"0001829126-25-007973","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"NeOnc subsidiary NuroMENA signs MSA with M42's IROS for UAE Phase 2b/3 trial of NEO100; board expanded","event_type":"other_material","confidence":"high","bullets":["MSA with IROS (affiliate of M42 and Mubadala) covers clinical research services in UAE for CNS cancer therapies.","First work order: Phase 2b/3 study of intranasal NEO100 in progressive/recurrent GBM and Grade III astrocytomas.","Estimated budget of $2.4M in service fees plus $0.1M pass-through costs, milestone-based payments.","NuroMENA board expands with Waleed K. Al Ali (CEO of Quazar Investment) and its Chairman, alongside Amir Heshmatpour and others.","Company retains all IP and data from studies under MSA; agreement governed by Abu Dhabi Global Market law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144905,"accession_number":"0001829126-25-007323","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc receives FDA authorization to proceed with Phase II clinical trial of NEO212 for brain cancer","event_type":"regulatory","confidence":"high","bullets":["FDA cleared NEO212-01 Phase IIa/IIb after Phase I showed safe dosing up to 810 mg daily days 1–5 of 28-day cycle.","Patient enrollment expected to begin before end of 2025 at up to 16 U.S. cancer centers including Cleveland Clinic, Duke, and USC.","NEO212 is an oral chemical conjugate of TMZ (Temodar) and NEO100 (perillyl alcohol), designed to enhance blood-brain barrier penetration.","Company believes NEO212 could replace TMZ as standard of care for glioblastoma, astrocytoma, and other CNS cancers.","CEO Dr. Thomas Chen and Executive Chairman Amir Heshmatpour highlighted milestone as transformative for brain cancer treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144904,"accession_number":"0001829126-25-006673","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","2.01","2.02","3.02","5.02","7.01","9.01"],"status":"ready","headline":"NeOnc acquires JandB Holdings for ~120k shares; Q2 net loss $5.68M; $50M partnership finalised","event_type":"other_material","confidence":"high","bullets":["Acquired 100% of JandB Holdings for ~120k shares of common stock valued at $25 per share.","Q2 2025 net loss $5.68M ($0.30 per share) vs $4.52M ($0.27) in Q2 2024.","G&A expenses $984K, R&D $677K; both increased YoY due to trial expansion and partnership costs.","$50M strategic partnership with Quazar Investment finalised; GCC & MENA clinical trials platform to launch.","Director Ming-Fu Chiang resigned; Ishwar Puri elected to board effective August 18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144896,"accession_number":"0001829126-25-006524","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K/A","filed_at":"2025-08-20T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"NeOnc Technologies restates Q1 2025 financials due to RSU compensation error","event_type":"other","confidence":"high","bullets":["Overstated non-cash share-based compensation on 1,486,667 RSUs issued Jan 4, 2024; assumed full vesting by Mar 31, 2025.","Actual vesting over 22 months; only 15 months vested as of Mar 31, 2025, requiring restatement.","Discovered Aug 13, 2025; management and audit committee concluded March 31, 2025 10-Q no longer reliable.","Restated figures included in the Company's June 30, 2025 10-Q filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144903,"accession_number":"0001829126-25-006425","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"NeOnc Technologies restates Q1 2025 financials for overstated share-based compensation","event_type":"other_material","confidence":"high","bullets":["Overstated non-cash share-based compensation expense on 1,486,667 RSUs issued Jan 4, 2024, due to incorrect assumption of full vesting by March 31, 2025.","RSUs actually vest over 22 months; only 15 months had vested as of March 31, 2025, resulting in a lower non-cash expense.","Company and audit committee concluded the March 31, 2025 Form 10-Q financial statements should no longer be relied upon.","Restatement will be fully presented in the Form 10-Q for the quarter ended June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144902,"accession_number":"0001829126-25-006210","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc secures $2.5M NIH grants for NEO212; finalizes $50M Quazar partnership","event_type":"other_material","confidence":"high","bullets":["Awarded two NIH STTR grants totaling $2.5M to advance NEO212 in gliomas and leukemia.","$400K Phase 1 grant supports NEO212 preclinical study in AML; $2.1M Phase 2 grant targets newly diagnosed gliomas.","NuroMENA Holdings Ltd. incorporated by Abu Dhabi Global Market, clearing all contingencies for $50M investment from Quazar Investment.","Partnership will fund CNS platform launch in MENA region and accelerate NEO212/NEO100 clinical programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144901,"accession_number":"0001829126-25-005708","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"NeOnc signs $50M strategic partnership with Quazar and acquires AI/quantum IP for $3.5M","event_type":"m_and_a","confidence":"high","bullets":["Quazar to acquire 1.4M NeOnc shares at $25/share ($35M); $15M for UAE clinical trials and infrastructure.","Initial $400k subscription for 2.5M NuroMENA shares; future $50M round at $25/share could dilute NeOnc's stake to ~38%.","Definitive LOI to acquire AI, 3D bioprinting, and quantum modeling IP from Dr. Ishwar K. Puri for $3.5M ($500k cash + $3M stock).","Dr. Ishwar K. Puri appointed to NeOnc's Board of Directors; he is USC SVP of Research and Innovation, top 0.4% scholar globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144900,"accession_number":"0001829126-25-005605","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"NeOnc to acquire patent from McMaster University in stock deal valued at ~$3M","event_type":"m_and_a","confidence":"high","bullets":["Enters binding LOI to acquire all equity of new LLC from Dr. Ishwar Puri and Beth Levinson.","LLC will acquire US Patent No 11,788,057 B2 from McMaster University for $500K cash funded by NeOnc note.","Purchase price: 120,000 NeOnc shares valued at $25 each (approx. $3M), less transaction fees.","Upon closing, Dr. Ishwar Puri appointed to NeOnc's Board of Directors.","Transaction subject to due diligence, LLC formation, and patent transfer agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144899,"accession_number":"0001829126-25-005378","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc Technologies executes sub-license for NEO100/NEO212 in MENA, milestone toward $50M Quazar deal","event_type":"other_material","confidence":"high","bullets":["NeOnc executed sub-license agreement with its Abu Dhabi subsidiary NuroCure for NEO100 and NEO212, covering UAE, GCC, and MENA.","This is the second of five conditions to close a $50M strategic investment from Quazar Investment at $25 per share.","Proposed structure: 70% of proceeds for NeOnc common stock, 30% for clinical trials and infrastructure in MENA.","Remaining conditions to be satisfied within 120 days, including legal formation of NuroMENA/NuroCure and finalizing offering documents.","Management also highlighted recent Russell Microcap Index inclusion as part of its capital markets strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144898,"accession_number":"0001829126-25-005280","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"NeOnc Technologies raises $5M in convertible notes with 20% OID and short-term maturity","event_type":"debt","confidence":"high","bullets":["Issued $5,000,000 aggregate principal amount of convertible promissory notes to unaffiliated accredited investors.","Notes carry 20% original issue discount, net proceeds ~$4,000,000; mature Oct 16 & 18, 2025.","Maturity may be extended up to three months with additional 5% OID per month.","Upon default, notes convertible at 80% of lowest closing price in prior 5 trading days.","Offered under Rule 506(b) as unregistered sale, exempt from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144897,"accession_number":"0001829126-25-005008","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc signs $50M non-binding term sheet with Quazar for UAE clinical platform expansion","event_type":"other_material","confidence":"high","bullets":["$50M equity investment at $25/share from Quazar Investment; board approved June 30, 2025.","Formation of NuroMENA Holdings and NuroCure in UAE to run clinical trials for NEO100 and NEO212.","70% of funds to buy NTHI common stock at $25/share; 30% for clinical trials and infrastructure.","Conditions include sub-license from USC Stevens Center, offering docs, and two-year plan within 120 days.","Partnership leverages Cleveland Clinic Abu Dhabi for trials under US FDA protocols."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163294,"accession_number":"0001829126-25-004450","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeOnc Technologies appoints Dr. Josh Neman as Chief Clinical Officer","event_type":"leadership","confidence":"high","bullets":["Dr. Josh Neman, PhD, appointed CCO; formerly Associate Professor at USC Keck School and Scientific Director of USC Brain Tumor Center.","He will lead clinical strategy for four trials, including NEO100 approaching Phase 2a completion with full enrollment ahead of schedule.","Neman's research on tumor-neuron interactions and GABAergic signaling supports FDA approval path and AI/quantum computing integration.","Appointment aims to accelerate precision therapies for CNS cancers; NeOnc holds 176 patents worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163293,"accession_number":"0001829126-25-004324","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"NeOnc Technologies appoints Josh Neman as Chief Clinical Officer","event_type":"leadership","confidence":"high","bullets":["Josh Neman appointed Chief Clinical Officer effective June 5, 2025; base salary $165,000/year.","Granted 200,000 RSUs: 1/3 vest Dec 30, 2025; 1/3 in 29 monthly installments; 1/3 performance-based.","Neman will continue his role as Associate Professor at USC Keck School of Medicine.","Neman also serves as CEO of Synaptical Inc. and CNSMENDER Consulting.","Employment term is 12 months with automatic annual renewal; at-will employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163292,"accession_number":"0001829126-25-004186","cik":1979414,"company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NeOnc COO Patrick Walters retires June 1, 2025; no replacement announced","event_type":"leadership","confidence":"high","bullets":["Patrick Walters notified the board on May 28, 2025 of his retirement as COO.","Retirement effective June 1, 2025; no successor named in the filing.","Company has not disclosed any interim or permanent replacement plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}